Esperion Therapeutics, Inc.
Quick facts
Marketed products
Phase 3 pipeline
- ETC-1002 · Cardiovascular
ETC-1002 activates AMP-activated protein kinase (AMPK) to reduce cholesterol synthesis and increase cholesterol catabolism, thereby lowering LDL cholesterol levels.
Phase 1 pipeline
- [14C-ETC-1002]
Radiolabeled tracer compound used to study the pharmacokinetics and metabolism of bempedoic acid.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Esperion Therapeutics, Inc.
What are Esperion Therapeutics, Inc.'s marketed drugs?
Top marketed products include Ezetimibe 10mg.
What is Esperion Therapeutics, Inc.'s pipeline?
Esperion Therapeutics, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include ETC-1002.
Related
- Ezetimibe 10mg
- Sector hub: All tracked pharma companies